The UK’s 10-Year Life Sciences Plan and a $5.13bn US investment commitment are backing a manufacturing
scale-up. The companies that benefit will need international production partners.
UK life sciences manufacturing employs 111,200 people across 2,010 sites – a figure that increased by 16,400 in just two years. The sector has historically excelled at discovery but struggled with manufacturing scale-up and commercialisation. The UK government’s 10-Year Life Sciences Plan, published in July 2025, is a direct attempt to close that gap: it targets foreign direct investment in manufacturing, NHS reform as a commercial signal, and cluster development that ties academic, clinical, and manufacturing capabilities into coherent geographic hubs.
The supply chain dimension is where the investment story becomes international. UK life sciences companies
scaling manufacturing operations – in cell and gene therapy, biomanufacturing, medical devices, and pharmaceutical production – require supply chains that are geographically diversified, regulatory-credible, and operationally reliable. Post-COVID vulnerabilities and 2026’s tariff environment are accelerating the transition from single-source to distributed supply chain models. The companies receiving UK manufacturing investment are simultaneously evaluating international production partnerships across markets with compatible regulatory frameworks.
The investment response domestically has been material. The US-UK Technology Prosperity Deal saw Prologis
commit $5.13 billion to UK science infrastructure, with Cambridge identified by Beauhurst as the UK’s most
investible hub for science and ranked first in Europe for deep-tech venture capital per capita. The Life Sciences Innovative Manufacturing Fund is providing direct capital support for manufacturing expansion. Clinical trial timelines are being reduced from 250 days to 150 days – a structural improvement in the UK’s ability to attract research-led investment.
The destinations best placed to capture this secondary investment flow are those that can offer regulatory alignment with UK and EU standards, skilled manufacturing talent in relevant disciplines, developed life sciences infrastructure, and established commercial relationships with British companies. This is a specific proposition – and the companies evaluating it will engage with precision.
The UK life sciences manufacturing build-out is creating both domestic investment and an international supply
chain reconfiguration. The destinations that position themselves inside that reconfiguration early will be part of the announcement, not simply aware of it.
Nueconomy operates directly in the UK and tracks expansion intent among British life sciences manufacturing
companies through CUE.
If you are a destination market positioning for UK life sciences manufacturing supply chain investment, we can help identify the right companies and build the right case.
hello@nueconomy.co · thenueconomy.com
Related: UK Life Sciences Is Restructuring Its Supply Chain
